Melinta Therapeutics

From Wikipedia, the free encyclopedia
  (Redirected from Rib-X Pharmaceuticals)
Jump to navigation Jump to search
Melinta Therapeutics
Public company
Traded asNASDAQMLNT
Russell 2000 Index component
IndustryPharmaceutical
Founded2000
HeadquartersNew Haven, CT
Area served
Worldwide
ProductsBroad-spectrum antibiotics
Websitehttp://melinta.com/

Melinta Therapeutics, founded in 2000 as Rib-X Pharmaceuticals, is an American publicly traded biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital and community settings. The company is located in New Haven, Connecticut.[1]

In mid-2011 Sanofi entered into a global research collaboration and licensing option with the company to develop and commercialize novel antibiotics.[2] It was renamed Melinta Therapeutics in 2013.[3]

One of its products, delafloxacin (Baxdela), a fluoroquinolone antibiotic acquired from Wakunaga Pharmaceutical in 2006,[2] was approved by the FDA in 2017.[4]

As of 2016 the company was also developing radezolid, a next-generation oxazolidinone for bacterial acne.[3]

References[edit]

  1. ^ Carroll, John (2011). "Rib-X Pharmaceuticals - 2011 Fierce 15". FierceBiotech.
  2. ^ a b Cartwright, Heather (12 July 2011). "Rib-X Pharmaceuticals Signs Global Antibiotic Research Collaboration with Sanofi". PharmaDeals Review (7). doi:10.3833/pdr.v2011i7.1494. Archived from the original on 25 April 2012.
  3. ^ a b Stearns, John (August 1, 2016). "Melinta Therapeutics takes aim at deadly drug-resistant bacteria". Hartford Business Journal.
  4. ^ Osborne, Randy (20 June 2017). "Melinta's I.V., oral delafloxacin wins FDA nod in skin infections". BioWorld.

External links[edit]